Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  letrozole
Find trials that include:  Any drugs shown
Results 1-25 of 34 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70, Postmenopausal
Trial IDs: A5481027, NCI-2015-01375, JS14185, NCT02297438
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011A2404, NCI-2016-01811, NCT02941926
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AFT-38, NCI-2017-00206, NCT02947685
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011H2301, NCI-2017-00678, NCT03081234
Dovitinib Lactate in Combination With Anastrozole, Exemestane, or Letrozole in Treating Patients With Hormone-Receptor Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-535, NCI-2013-00749, NCT01484041
Copanlisib, Letrozole, and Palbociclib in Treating Patients with Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 16-001271, NCI-2017-00435, NCT03128619
Pazopanib Hydrochloride and Anastrozole or Letrozole in Treating Patients With Advanced Hormone-Resistant Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117513, NCI-2012-00494, NCT01466972
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CRAD001Y24135, NCI-2012-02282, 2012-003065-17, NCT01698918
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-11, NCI-2015-00998, WI180455, NCT02296801
Ribociclib and Letrozole in Treating Patients with Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1561, NCI-2015-02181, NCT02657928
Letrozole with or without Ribociclib before Surgery in Treating Women with Stage II-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011XUS10T, NCI-2016-00423, STUDY00002972, NCT02712723
Pembrolizumab and Doxorubicin Hydrochloride or Anti-estrogen Therapy in Treating Patients with Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15295, NCI-2015-02194, NCT02648477
Tamoxifen Citrate or Letrozole with or without Palbociclib in Treating Patients with Stage I-III Invasive Breast Cancer before Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-052, NCI-2016-00893, NCT02764541
Palbociclib, Letrozole, and Trastuzumab Before Surgery in Treating Patients with Estrogen Receptor Positive and HER2 Positive Stage II-III Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201610019, NCI-2016-01516, NCT02907918
Paclitaxel and Carboplatin before Surgery in Treating Nigerian Women with Stage IIA-IIIC Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: IRB15-1005, NCI-2017-00754, NCT03058939
A Study of LY3023414 in Participants With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13517, NCI-2016-01472, I6A-MC-CBBA, NCT01655225
Alpelisib and Letrozole with or without Trastuzumab in Post-menopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BRE 12101, NCI-2013-00102, SU2C B07, CBYL719XUS03T, NCT01791478
Start Over